Intelligence · Clinical Development
Pipeline search results
Programs matching “Novartis” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 341 pipeline programs matching "Novartis" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
CLOU064P12301
Novartis Pharmaceuticals
Secondary progressive multiple sclerosis
1 trial -
CNIO752A12301
Novartis Pharmaceuticals
Participants with Progressive Supranuclear Palsy Richardson Syndrome (PSP-RS)
1 trial -
COAV101A12308
Novartis Pharmaceuticals
Spinal Muscular Atrophy
1 trial -
COMB157G23101
Novartis Pharmaceuticals
relapsing multiple sclerosis (RMS)
1 trial -
COMB157G2399
Novartis Pharmaceuticals
Relapsing multiple sclerosis (RMS)
1 trial -
COMB157G3301
Novartis Pharmaceuticals
relapsing multiple sclerosis (RMS)
1 trial -
CPI-0610, CPI-0610
Novartis Pharmaceuticals
Myelofibrosis, Myeloproliferative Neoplasms (Myelofibrosis and Essential Thrombocythemia)
1 trial -
CTQJ230A12301
Novartis Pharmaceuticals
Cardiovascular Disease
1 trial -
CTQJ230A12302
Novartis Pharmaceuticals
Apheresis
1 trial -
CTQJ230A12304
Novartis Pharmaceuticals
Atherosclerotic cardiovascular disease (ASCVD)
1 trial -
CVAY736A2301
Novartis Pharmaceuticals
Sjögren’s Syndrome
1 trial -
CVAY736A2302
Novartis Pharmaceuticals
Sjögren’s Syndrome
1 trial -
CVAY736B2201
Novartis Pharmaceuticals
Autoimmune hepatitis
1 trial -
CVAY736F12301
Novartis Pharmaceuticals
Systemic Lupus Erythematosus
1 trial -
CVAY736F12302
Novartis Pharmaceuticals
Systemic Lupus Erythematosus
1 trial -
CVAY736K12301
Novartis Pharmaceuticals
Lupus nephritis
1 trial -
CVAY736K12301E1
Novartis Pharmaceuticals
Lupus nephritis
1 trial -
CVAY736O12301
Novartis Pharmaceuticals
warm autoimmune haemolytic anaemia (wAIHA)
1 trial -
CVAY736Q12301
Novartis Pharmaceuticals
Primary immune thrombocytopenia (ITP)
1 trial -
Capmatinib
Novartis Pharmaceuticals
Carcinoma, Non-Small-Cell Lung
1 trial -
Dabrafenib
Novartis Pharmaceuticals
Malignant Melanoma
1 trial -
Deferasirox
Novartis Pharmaceuticals
Transfusion-dependent Iron Overload
1 trial -
EVEROLIMUS
Novartis Pharmaceuticals
Refractory seizures associated with tuberous sclerosis complex
1 trial -
Everolimus
Novartis Pharmaceuticals
Advanced NET of GI Origin
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.